Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia

References

• McGrathJSahaSChantDWelhamJSchizophrenia: a concise overview of incidence, prevalence, and mortalityEpidemiol Rev2008301677618480098
   PubMed Web of Science ®Google Scholar
• VosTFlaxmanADNaghaviMYears lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet2013380985921632196
   Web of Science ®Google Scholar
• MurrayCJLopezADJamisonDTThe global burden of disease in 1990: summary results, sensitivity analysis and future directionsBull World Health Org19947234955098062404
   PubMed Web of Science ®Google Scholar
• CarràGCazzulloCLClericiMThe association between expressed emotion, illness severity and subjective burden of care in relatives of patients with schizophrenia. Findings from an Italian populationBMC Psychiatry201212114022974195
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health UKPsychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014LondonNational Institute for Health and Care Excellence (UK) NICE guidelines updated in 2014
   Google Scholar
• KnappMMangaloreRSimonJThe global costs of schizophreniaSchizophr Bull200430227929315279046
   PubMed Web of Science ®Google Scholar
• HowesODMurrayRMSchizophrenia: an integrated sociodevelopmental-cognitive modelLancet201438399291677168724315522
   PubMed Web of Science ®Google Scholar
• SahaSChantDMcGrathJA systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?Arch Gen Psychiatry200764101123113117909124
   PubMed Web of Science ®Google Scholar
• WiersmaDWanderlingJDragomireckaESocial disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centresPsychol Med200030051155116712027051
   PubMed Web of Science ®Google Scholar
• MontemagniCFrieriTRoccaPSecond-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeNeuropsychiat Dis Treat201612917929
   PubMed Web of Science ®Google Scholar
• AlmondSKnappMFrancoisCToumiMBrughaTRelapse in schizophrenia: costs, clinical outcomes and quality of lifeBr J Psychiatry2004184434635115056580
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDEThe cost of relapse and the predictors of relapse in the treatment of schizophreniaBMC Psychiatry2010101220059765
   PubMed Web of Science ®Google Scholar
• WeidenPJOlfsonMCost of relapse in schizophreniaSchizophr Bull19952134194297481573
   PubMed Web of Science ®Google Scholar
• WyattRJResearch in schizophrenia and the discontinuation of antipsychotic medicationsSchizophr Bull1997231399050108
   PubMed Web of Science ®Google Scholar
• LiebermanJAAlvirJMKoreenAPsychobiologic correlates of treatment response in schizophreniaNeuropsychopharmacology199614Suppl 313S21S8866739
   PubMed Web of Science ®Google Scholar
• BirchwoodMToddPJacksonCEarly intervention in psychosis. The critical period hypothesisBr J Psychiatry Suppl19981723353599764127
   PubMedGoogle Scholar
• McEvoyJPThe importance of early treatment of schizophreniaBehav Healthc20072744043
   Google Scholar
• MurrayRMQuattroneDNatesanSShould psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?Br J Psychiatry2016209536136527802977
   PubMed Web of Science ®Google Scholar
• PantelisCYücelMWoodSJMcGorryPDVelakoulisDEarly and late neurodevelopmental disturbances in schizophrenia and their functional consequencesAust N Z J Psychiatry200337439940612873323
   PubMed Web of Science ®Google Scholar
• PerkinsDOGuHBotevaKLiebermanJARelationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysisAm J Psychiatry2005162101785180416199825
   PubMed Web of Science ®Google Scholar
• HasanAFalkaiPWobrockTWorld Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for SchizophreniaWorld federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistanceWorld J Biol Psychiatry201213531837822834451
   PubMed Web of Science ®Google Scholar
• HasanAFalkaiPWobrockTWFSBP Task force on Treatment Guidelines for SchizophreniaWorld federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effectsWorld J Biol Psychiatry201314124423216388
   PubMed Web of Science ®Google Scholar
• LindenmayerJPLiu-SeifertHKulkarniPMMedication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJ Clin Psychiatry200970799099619497244
   PubMed Web of Science ®Google Scholar
• SuzukiTUchidaHTakeuchiHTsuboiTHiranoJMimuraMA review on schizophrenia and relapse a quest for user-friendly psychopharmacotherapyHum Psychopharmacol201429541442625055792
   PubMed Web of Science ®Google Scholar
• EmsleyRChilizaBAsmalLHarveyBHThe nature of relapse in schizophreniaBMC Psychiatry20131315023394123
   PubMed Web of Science ®Google Scholar
• ColdhamELAddingtonJAddingtonDMedication adherence of individuals with a first episode of psychosisActa Psychiatr Scand2002106428629012225495
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• MillerBJA review of second-generation antipsychotic discontinuation in first-episode psychosisJ Psychiatr Pract200814528930018832960
   PubMed Web of Science ®Google Scholar
• MillerBJBodenheimerCCrittendenKSecond-generation antipsychotic discontinuation in first episode psychosis: an updated reviewClin Psychopharmacol Neurosci201192455323429653
   PubMedGoogle Scholar
• NovickDHaroJMSuarezDPerezVDittmannRWHaddadPMPredictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophreniaPsychiatry Res20101762–310911320185182
   PubMed Web of Science ®Google Scholar
• VelliganDILamFEreshefskyLMillerALPsychopharmacology: perspectives on medication adherence and atypical antipsychotic medicationsPsychiatr Serv200354566566712719495
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• KahnRSFleischhackerWWBoterHEUFEST study groupEffectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet200837196181085109718374841
   PubMed Web of Science ®Google Scholar
• Di MatteoMRVariations in patients’ adherence to medical recommendations: a quantitative review of 50 years of researchMed Care200442320020915076819
   PubMed Web of Science ®Google Scholar
• JónsdóttirHOpjordsmoenSBirkenaesABMedication adherence in outpatients with severe mental disorders: relation between self-reports and serum levelJ Clin Psychopharmacol201030216917520520290
   PubMed Web of Science ®Google Scholar
• DassaDBoyerLBenoitMBourcetSRaymondetPBottaiTFactors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage healthcare systemAust N Z J Psychiatry2010441092192820932206
   PubMed Web of Science ®Google Scholar
• VelliganDIWangMDiamondPRelationships among subjective and objective measures of adherence to oral antipsychotic medicationsPsychiatr Serv20075891187119217766564
   PubMed Web of Science ®Google Scholar
• KaneJMKishimotoTCorrellCUNon-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategiesWorld Psychiatry201312321622624096780
   PubMed Web of Science ®Google Scholar
• HaddadPMBrainCScottJNonadherence with antipsychotic medication in schizophrenia: challenges and management strategiesPatient Relat Outcome Meas20145436225061342
   PubMedGoogle Scholar
• BrissosSVeguillaMRTaylorDBalanzá-MartinezVThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisalTher Adv Psychopharmacol20144519821925360245
   PubMedGoogle Scholar
• LauberCEichenbergerALuginbühlPKellerCRösslerWDeterminants of burden in caregivers of patients with exacerbating schizophreniaEur Psychiatry200318628528914611923
   PubMed Web of Science ®Google Scholar
• LeuchtSTardyMKomossaKAntipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysisLancet201237998312063207122560607
   PubMed Web of Science ®Google Scholar
• WiersmaDNienhuisFJSlooffCJGielRNatural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohortSchizophr Bull199824175859502547
   PubMed Web of Science ®Google Scholar
• EmsleyROosthuizenPKoenLNiehausDMartinezLComparison of treatment response in second-episode versus first-episode schizophreniaJ Clin Psychopharmacol2013331808323277247
   PubMed Web of Science ®Google Scholar
• LlorcaPMAbbarMCourtetPGuillaumeSLancrenonSSamalinLGuidelines for the use and management of long-acting injectable antipsychotics in serious mental illnessBMC Psychiatry20131334024359031
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• PatelMXDavidASWhy aren’t depot antipsychotics prescribed more often and what can be done about it?Adv Psychiatr Treat2005113203211
   Google Scholar
• TaylorMNgKYShould long-acting (depot) antipsychotics be used in early schizophrenia? A systematic reviewAust N Z J Psychiatry201347762463023209308
   PubMed Web of Science ®Google Scholar
• EreshefskyLMascarenasCAComparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamicsJ Clin Psychiatry200364161823
   PubMedGoogle Scholar
• GefvertOErikssonBPerssonPPharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta™) in patients with schizophreniaInt J Neuropsychopharmacol200581273615710053
   PubMed Web of Science ®Google Scholar
• WhitworthABFleischhackerWWAdverse effects of antipsychotic drugsCurr Opin Psychiatry1994717175
   Google Scholar
• MoncrieffJDoes antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapseActa Psychiatr Scand2006114131316774655
   PubMed Web of Science ®Google Scholar
• KaneJMGarcia-RiberaCClinical guideline recommendations for antipsychotic long-acting injectionsBr J Psychiatry Suppl200952S63S6719880920
   PubMedGoogle Scholar
• OstuzziGBighelliISoRFurukawaTABarbuiCDoes formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studiesSchizophr Res2016183102127866695
   PubMed Web of Science ®Google Scholar
• BiagiECapuzziEColmegnaFLong-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthlyAdv Ther20173451036104828382557
   PubMed Web of Science ®Google Scholar
• CorrellCUKishimotoTKaneJMRandomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesDialogues Clin Neurosci201113215517221842613
   PubMedGoogle Scholar
• FagioliniARoccaPDe GiorgiSSpinaEAmodeoGAmoreMClinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studiesPsychiatry Res201724725726427936437
   PubMed Web of Science ®Google Scholar
• BernardoMBioqueMThree-month paliperidone palmitate-a new treatment option for schizophreniaExpert Rev Clin Pharmacol20169789990427206330
   PubMed Web of Science ®Google Scholar
• RavenstijnPRemmerieBSavitzAPharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label studyJ Clin Pharmacol201656333033926189570
   PubMed Web of Science ®Google Scholar
• BerwaertsJLiuYGopalSEfficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trialJAMA Psychiatry201572883083925820612
   PubMed Web of Science ®Google Scholar
• SavitzAJXuHGopalSEfficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority studyInt J Neuropsychopharmacol2016197Pyw01826902950
   PubMed Web of Science ®Google Scholar
• SavitzAJXuHGopalSNuamahIHoughDMathewsMPaliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and non-inferiority studyIntern Clin Psychopharmacol2017326329336
   PubMed Web of Science ®Google Scholar
• KatzEGHauberBGopalSPhysician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trialsPatient Prefer Adherence2016102127213927799749
   PubMed Web of Science ®Google Scholar
• ChirilaCNuamahIWoodruffKHealth care resource use analysis of paliperidone palmitate 3 month injection from two phase 3 clinical trialsCurr Med Res Opin20173361083109028277864
   PubMed Web of Science ®Google Scholar
• GopalSXuHMcQuarrieKCaregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studiesNPJ Schizophr2017312328751663
   PubMed Web of Science ®Google Scholar
• WeidenPJKimEBermakJTurkozIGopalSBerwaertsJDoes half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidoneJ Clin Psychiatry2017787e813e82028640988
   PubMed Web of Science ®Google Scholar
• KramerMSimpsonGMaciulisVPaliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol200727161417224706
   PubMed Web of Science ®Google Scholar
• HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res20101162–310711719959339
   PubMed Web of Science ®Google Scholar
• JoshiKLafeuilleMHBrownBBaseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world settingCurr Med Res Opin201733101763177228741387
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyTrevicta (paliperidone palmitate) prolonged release suspension for injection: EU summary of product characteristics2016 Available from: http://www.ema.europa.eu/Accessed April 30, 2017
   Google Scholar
• Janssen Pharmaceuticals IncInvega Trinza (paliperidone palmitate) extended-release injectable suspension, for intramuscular use: US prescribing information2016 Available from: http://www.janssencns.com/Accessed April 30, 2017
   Google Scholar
• GopalSVermeulenANandyPPractical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophreniaCurr Med Res Opin201531112043205426306819
   PubMed Web of Science ®Google Scholar
• GildayENasrallahHAClinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophreniaRev Recent Clin Trials2012712922023179
   PubMedGoogle Scholar
• KarlssonPHargarterLDenckerEPharmacokinetics and dopamine d2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115)Pharmacopsychiatry2007405A106
   Web of Science ®Google Scholar
• RemingtonGMamoDLabelleAA PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidoneAm J Psychiatry2006163339640116513859
   PubMed Web of Science ®Google Scholar
• NasrallahHAAtypical antipsychotic-induced metabolite side effects: insights from receptor-binding profilesMol Psychiatry2008131273517848919
   PubMed Web of Science ®Google Scholar
• RodríguezFZVegaCBHernándezMSMacíasJGLealFVUse of paliperidone palmitate throughout a schizoaffective disorder patient’s gestation periodPharmacopsychiatry2017501384027414740
   PubMed Web of Science ®Google Scholar
• ÖzdemirAKPakŞCCananFGeçiciÖKuloğluMGücerMKPaliperidone palmitate use in pregnancy in a woman with schizophreniaArch Womens Ment Health201518573974025599999
   PubMed Web of Science ®Google Scholar
• OstuzziGPapolaDGastaldonCBarbuiCNew EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence baseEpidemiol Psychiatr Sci201726323123328004623
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (2012)Guideline on Clinical Investigation of Medicinal Products, Including Depot Preparations in the Treatment of SchizophreniaEMA/CHMP/40072/2010 Rev. 12012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133437.pdfAccessed April 30, 2017
   Google Scholar
• EinarsonTRBerezaBGGarcia LlinaresIGonzález Martín MoroBTedouriFVan ImpeKCost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in SpainJ Med Econ201720101039104728678566
   PubMed Web of Science ®Google Scholar
• EinarsonTRBerezaBGTedouriFVan ImpeKDeneeTRDriesPJCost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the NetherlandsJ Med Econ201720111187119928762843
   PubMed Web of Science ®Google Scholar
• European Medicine AgencySummary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004066/WC500180640.pdfAccessed October 30, 2017
   Google Scholar